Abrogation of bleomycin induced inflammation and lung fibrosis by angiotensin AT1 receptor antagonist. Relevance of PGE-2 modulation Source: Eur Respir J 2005; 26: Suppl. 49, 82s Year: 2005
Protective effect of leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
6-aminonicotinamide ameliorates pulmonary fibrosis by suppressing the TGF-beta1 activated Smad signalling pathway Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 111s Year: 2007
A role of prostaglandin D2 receptor, CRTH2, on bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008
Inhibitory effect of PGE2 receptor subtype, EP4, in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease Year: 2007
Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2009; 34: 1444-1451 Year: 2009
Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing VEGF expression Source: Eur Respir J 2004; 24: Suppl. 48, 129s Year: 2004
Toll-like receptor stimulation induces airway hyperresponsiveness to bradykinin, an effect mediated by JNK and NF-κB signaling pathways Source: Eur Respir J 2005; 26: Suppl. 49, 732s Year: 2005
Synergistic action of formoterol on budesonide-generated decrease of proteoglycan production by activated lung fibroblasts is mediated via β-adrenergic receptor and is dependent on glucocorticoid receptor Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Surfactant protein A modulate bleomycin-induced lung injury in toll-like receptor 2 dependent pathway Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010
Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension Source: Eur Respir J 2016; 48: 470-483 Year: 2016
SD-208 an orally active TGF-β1 receptor antagonist inhibits TGF-β1 induced progressive lung fibrosis in rat Source: Annual Congress 2003 - Animal models of lung injury: useful or not? Year: 2003
Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice Source: Eur Respir J 2008; 32: 426-436 Year: 2008
PAR-2 antagonist inhibits bleomycin-induced lung fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019
Four-and-a-half-LIM-domain (FHL)-2 acts as an enhancer of TGF-beta signaling in pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 296s Year: 2007
Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis Source: International Congress 2019 – Damage and remodelling in pulmonary fibrosis Year: 2019
Imbalanced expression of the type I TGF-beta receptors ALK-1 in pulmonary fibrosis Source: Annual Congress 2009 - Mechanisms of pulmonary inflammation and fibrosis Year: 2009
Concomitant exposure to nicotine and endotoxin in vitro induces murine airway hyperreactivity possibly via nicotine-induced upregulation of toll-like receptors Source: Annual Congress 2011 - New mechanisms in airway disease Year: 2011
Late Breaking Abstract: Anti-fibrogenic effects of the endothelin-A receptor antagonist ambrisentan in a mouse pulmonary fibrosis model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010